

Certificate of Mailing	
Date of Deposit <u>7/31/01</u>	Label Number: <u>EL 834597195 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u>Guy Beardsley</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Krystal et al. Art Unit: Not yet assigned
Serial No.: Not yet assigned Examiner Not yet assigned
Filed: July 31, 2001 Customer No.: 21559
Title: PEPTIDES AND THEIR USE TO AMELIORATE CELL DEATH

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of six pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of

the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.


As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

July 31, 2001



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Paul T. Clark
30,162

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

\\Clark-w2k1\documents\50216\50216.003004 Sequence Statement.wpd



21559

PATENT TRADEMARK OFFICE

SEQUENCE LISTING

<110> Krystal, Gerald
Rabkin, Simon W.

<120> Peptides and Their Use to Ameliorate
Cell Death

<130> 50216/003004

<150> US 09/294,457

<151> 1999-04-19

<150> US 08/759,599

<151> 1996-12-05

<150> US 60/008,233

<151> 1995-12-06

<160> 16

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 1

Ser Val Asp Val Glu Tyr
1 5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 2

Tyr Val Asp Val Asp Thr
1 5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<400> 3
Thr Val Asp Val Glu Tyr
1 5

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 4
Tyr Val Asp Val Asp Thr Asn Glu Leu Leu Lys
1 5 10

<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 5
Ser Val Asp Val Glu Tyr Thr Val Gln Phe Thr Pro Leu Asn Pro Asp
1 5 10 15

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 6
Ser Val Asp Val Glu Tyr Thr Gln Phe Thr Asp Phe Arg Gly Lys Leu
1 5 10 15
Thr Lys Leu Leu
20

<210> 7
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<400> 7
Ser Val Asp Val Glu Tyr Thr Val Gln Phe Thr Pro Leu Asn Pro Asp
1 5 10 15
Asp Asp Phe Arg Pro

<210> 8
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<400> 8
 Tyr Val Asp Val Asp Thr Asn Glu Leu Leu Lys Ser Glu Gln Leu Leu
 1 5 10 15
 Thr Ala Ser Glu
 20

<210> 9
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<400> 9
 Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg
 1 5 10 15
 Thr Gly Asp Arg
 20

<210> 10
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<400> 10
 Arg Leu Ile Leu Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Ala
 1 5 10 15
 Lys Glu Ala Glu
 20

<210> 11
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<400> 11
 Glu Val Thr Glu Glu Glu Glu Thr Val Pro Leu Lys Thr Leu Glu Ala

Lys	Val	Glu	Asp	Asn	His	Asp	Asp	Thr	Asn	Arg	Ile	Ile	Thr	Val	Tyr
		355					360					365			
Met	Gly	Lys	Arg	Pro	Glu	Gly	Glu	Asn	Ala	Ser	Tyr	His	Ala	Tyr	Asp
	370					375					380				
Lys	Asp	Arg	Tyr	Thr	Glu	Glu	Arg	Glu	Val	Tyr	Ser	Tyr	Leu	Arg	
385				390					395					400	
Tyr	Thr	Gly	Thr	Pro	Ile	Pro	Asp	Asn	Pro	Asp	Asp	Lys			
			405					410							

<210> 13
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<221> VARIANT
 <222> 1
 <223> Xaa=Ser or Tyr

<400> 13
 Xaa Val Asp Val
 1

<210> 14
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<221> VARIANT
 <222> 4
 <223> Xaa=Glu or Asp

<400> 14
 Val Asp Val Xaa
 1

<210> 15
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic polypeptide

<221> VARIANT
 <222> 1
 <223> Xaa=Ser or Tyr

<221> VARIANT
 <222> 5

<223> Xaa=Glu or Asp

<400> 15

Xaa Val Asp Val Xaa
1 5

<210> 16

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic polypeptide

<221> VARIANT

<222> 4

<223> Xaa=Glu or Asp

<221> VARIANT

<222> 5

<223> Xaa=Tyr or Thr

<400> 16

Val Asp Val Xaa Xaa
1 5